This website uses cookies. By using the site you are agreeing to our Privacy Policy.


HOME >> Investor Relations >> Corporate Profile & History

PRINT

Corporate Profile

All information correct as of June, 2018.
Company Name J-TECJapan Tissue Engineering Co., Ltd. (J-TEC)
Establishment February 1, 1999
Capitalization 4,958 million yen (as of March 31, 2018)
Business groups
  1. Regenerative Medicine Business
  2. Custom Development & Manufacturing Business
  3. R&D Support Business
Directors President and CEO: Ken-ichiro Hata, D.D.S., Ph.D.
Senior Executive Officer: Toshihiro Osuka
Managing Executive Officer: Toshiyuki Hara
Non - Executive Directors : Takatoshi Ishikawa
Toshikazu Ban
Masataka Akiyama
Tsutomu Tezuka
Corporate Officers Corporate Officers: Yukio Mori
Toru Kuroda
Masahito Obayashi
Masukazu Inoie
Auditors Auditors: Kiyotaka Kurahashi
Takahiro Kato
Kaoru Ogawa
Headquarters 6-209-1 Miyakitadori, Gamagori, Aichi 443-0022, Japan
TEL: +81-533-66-2020 FAX: +81-533-66-2019
e-mail:jtec-info@jpte.co.jp
Financial year ends March

Company History

Feb. 1999 Japan Tissue Engineering Co., Ltd established as a joint venture. Operations begun at Hama-cho, Gamagori.
Sep. 1999 Relocated the head office to Miyakidadori, Gamagori.
Nov. 2000 Awarded the Chubu Bureau of International Trade and Industry Prize in the New Business Awards Division of the Chubu New Business Awards, sponsored by the Chubu New Business Association.
Dec. 2000 Submitted application for government approval prior to a clinical trial of Autologous Cultured Epidermis.
Sept. 2001 Submitted application for government approval prior to a clinical trial of Autologous Cultured Cartilage.
Jan. 2002 Awarded a Special Incentive Award in the 15th Chunichi Industrial Technology Awards sponsored by the Chunichi Shimbun newspaper.
Mar. 2002 Obtained authorization to begin clinical trials of autologous cultured epidermis.
Aug. 2003 Full-scale entry into cornea cultivation in collaboration with an Italian eye bank (The Veneto Eye Bank Foundation).
Sep. 2003 Started multicenter clinical trials of autologous cultured epidermis.
Feb. 2004 Obtained authorization to begin clinical trials of autologous cultured cartilage.
May 2004 Started multicenter clinical trials of autologous cultured cartilage.
Jun. 2004 Awarded President of the Science Council of Japan's Award at the 16th Awards for Excellence in Collaboration Between Industry, Academia, and Government.
Oct. 2004 Submitted application for manufacturing and sales approval of Autologous Cultured Epidermis.
Nov. 2004 Completed construction of new premises and moved in.
Mar. 2005 Launched sales of LabCyte EPI-MODEL, a cultured human tissue for research use.
Oct. 2005 Awarded the Japan Bioventure Grand Prize, the top honor in the Fourth Japan Bioventure Grand Prize awards.
Nov. 2006 Awarded the highest prize in the New Business Awards 2006, sponsored by the Chubu Economic Federation.
Nov. 2006 Launched sales of LabCyte MELANO-MODEL, a cultured human tissue for research use.
Mar. 2007 Submitted clinical trial completion notification of Autologous Cultured Cartilage.
May. 2007 Submitted application for government approval prior to a clinical trial of Autologous Cultured Corneal Epithelium.
Aug. 2007 Developed Cell-Culture Kit for research use.
Oct. 2007 Received government approval to culture and sell Autologous Cultured Epidermis JACE® for serious burns treatment in Japan.
Nov. 2007 Submitted a request for health insurance listing of Autologous Cultured Epidermis.
Dec. 2007 Joined the JASDAQ Securities Exchange's Neo market on December 21.
May 2008 Entered into an Advisory Agreement with Prof. Howard Green of Harverd Medical School.
Jan. 2009 Autologous Cultured Epidermis JACE®: Listed as an item covered by the National Health Insurance in Japan.
Aug. 2009 Submitted application for manufacturing and sales of Autologous Cultured Cartilage.
Jul. 2010 Launched sales of LabCyte CORNEA-MODEL, a cultured human tissue for research use.
Oct. 2010 Issued new shares by third party allocation. The largest shareholder in J-TEC changed from NIDEK Co., Ltd. to FUJIFILM Corporation. (press release)
Dec. 2010 Established Singapore Representative Office. (press release)
Mar. 2011 Autologous Cultured Epidermis JACE®: Designated as a medical device for rare diseases for the treatment of epidermolysis bullosa.
Jul. 2012 Received Government Approval to Manufacture and Sell Autologous Cultured Cartilage JACC® in Japan (press release)
Sep. 2012 Closed Singapore Representative Office.
Apr. 2013 Autologous Cultured Cartilage JACC®: Listed as an item covered by the National Health Insurance in Japan.
Sep. 2013 Awarded the 5th MONOZUKURI Manufacturing Japan Grand Awards: Prime Minister’s Prize.
Jan. 2014 Awarded the 2013 Nikkei Superior Products and Services Awards: Nikkei Awards for Excellence.
Aug. 2014 Awarded the 12th Award for Persons of Merit in Industry-Academia-Government Collaboration (Minister of Health, Labour and Welfare Prize).
Oct. 2014 Started multicenter clinical trials of autologous cultured corneal epithelium.
Nov. 2014 Autologous Cultured Epidermis JACE®: Designated as an orphan regenerative medicine product for giant nevi.
Nov. 2014 Started consulting and contract cell processing business for medical institutions.
Dec. 2014 Fujifilm Holdings Corporation became a parent company of J-TEC. (press release)
Mar. 2015 Autologous Cultured Corneal Epithelium: Designated as an orphan regenerative medicine product for corneal stem cell damage.
Oct. 2015 Received government approval as a center for contract cell processing.
Jan. 2016 Autologous Cultured Epidermis “JACE”: Submitted supplemental application for Giant Nevi.
Apr. 2016 Started the Contract Development, Research, and Manufacturing Organization business specialized in regenerative medicine.
Sep. 2016 Autologous Cultured Epidermis “JACE”: Submitted supplemental application for Giant Nevi.
Dec. 2016 Started the Contract Development, Research, and Manufacturing Organization business specialized in regenerative medicine.
Sep. 2016 Received government approval to culture and sell Autologous Cultured Epidermis JACE® for Giant Nevi in Japan.
Dec. 2016 Autologous Cultured Epidermis JACE® for Giant Nevi: Listed as an item covered by the National Health Insurance in Japan.

Pagetop